A humanized anti-PD-1 monoclonal antibody can bind to the human PD-1 receptor and block the PD-1/PD-L1 pathway to restore the body’s anti-tumor immunity, thus forming the basis of cancer immunotherapy. Here, PDCD1 is linked to neoplasm.